December 03, 2013
Exela Pharma Sciences LLC and its subsidiaries asked a Delaware federal judge to reconsider a recent ruling that they infringed Cadence Pharmaceuticals Inc.'s patents by creating a generic version of injectable-painkiller Ofirmev, saying Monday that new evidence proved one of the patents invalid.
November 22, 2013
A Delaware federal judge has ruled against Exela Pharma Sciences LLC and its subsidiaries in favor of Cadence Pharmaceuticals Inc. in a patent infringement suit over plans to market a generic version of the injectable pain reliever Ofirmev, according to an opinion unsealed on Friday.
December 10, 2012
A Delaware federal judge on Friday asked the French government for help in deposing a Bristol-Myers Squibb Co. executive believed by Cadence Pharmaceuticals Inc. to have information critical to its pursuit of patent infringement claims over injectable acetaminophen treatment Ofirmev.
November 28, 2012
Generic-drug maker Perrigo Co. and its subsidiary Paddock Laboratories LLC have entered into a licensing agreement with Cadence Pharmaceuticals Inc., ending a Delaware patent dispute over Paddock's plans to make a generic version of Cadence's Ofirmev brand of injectable acetaminophen, the companies announced Wednesday.
August 19, 2011
Cadence Pharmaceuticals Inc. launched a patent infringement suit against generics makers Paddock Laboratories Inc. and Exela Pharma Sciences LLC in Delaware federal court on Thursday, seeking to block a generic version of Ofirmev, an injectable form of the pain reliever acetaminophen.